Semaglutide (CAS number: 99291-20-0) is a drug developed and produced by Danish pharmaceutical company Novo Nordisk. It is suitable for patients with type 2 diabetes. In recent years, it has become popular as a "magic weight-loss drug", although it has side effects. Scientists are exploring its application in fighting cancer and protecting cardiovascular and cerebrovascular diseases.
Factory Address: Jiutongda Office Building, Dongxihu District, Wuhan City, Hubei, China
Main products: Biochemicals
Contact number: +86 17683743113
E-MAIL：1414717232@qq.com
Factory Address: Unit B04, Building 17, No. 122 Yong'an Road, Hushuguan Town, Suzhou SND, China
Main products: Peptide
Contact number: +86 512-66891112
E-MAIL: sales@motifbiotech.com
Factory Address: No 18 Haishu Road, Yuhang District ,Hangzhou, Zhejiang, China
Main products: GMP Pharmaceutical Peptide
Contact number: +86 0575-83835818
E-MAIL: sales@peptide-china.com
Factory Address: Suit 101, Building 66, 320 lvlin road, Beicai pudong new area, Shanghai, China
Main products: Peptide
Contact number: +86-21-50835580
E-MAIL: PEPTIDE@SYNPEPTIDE.COM
On June 12, Propharma Co., Ltd. and Beijing Haijinge Pharmaceutical Technology Co., Ltd. reached a cooperation agreement on the clinical research of semaglutide injection. The two parties will cooperate on a number of aspects including clinical trial comparison, efficacy and safety evaluation, and clinical trial design of semaglutide injection.
According to a report on the British "Times" website on June 4, in a study involving 34,000 obese adults, researchers found that weight loss injections such as semaglutide can reduce the risk of cancer by 20%, providing a new weapon in the fight against cancer.
Recently, Livzon Pharmaceutical Group Co., Ltd. received the "Acceptance Notice". The domestic production drug registration application for semaglutide injection applied by its holding subsidiary Livzon Group Xinbeijiang Pharmaceutical Co., Ltd. was accepted by the Drug Administration.
Corey Able et al. from the University of Texas Medical Branch published a research paper in the International journal of impotence research exploring the effects of semaglutide on the sexual function of non-diabetic, obese male patients.